Teva Pharmaceutical Industries Ltd. announced the launch of the generic equivalent to Niaspan (niacin extended-release) tablets, 500, 750, and 1000mg in the United States.
Teva was first to file, making the product eligible for 180 days of marketing exclusivity.
Niaspan is marketed by AbbVie and used with diet to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia.
Niaspan had annual sales of approximately $1.12 billion in the United States, according to IMS data as of June 30, 2013.
Date: September 20, 2013